TLIS Talis Biomedical

Talis Biomedical to Participate in Upcoming BofA Securities 2021 Virtual Healthcare Conference

Talis Biomedical to Participate in Upcoming BofA Securities 2021 Virtual Healthcare Conference

MENLO PARK, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (“TLIS”), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that the company will be participating in the BofA Securities 2021 Virtual Healthcare Conference.

Talis Biomedical’s management is scheduled to participate in the conference on Wednesday, May 12, 2021, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. Interested parties can access the live and archived webcast via the page of the investor section of the company’s website at .

About Talis Biomedical

Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost, and rapid molecular testing for infectious diseases at the point-of-care. The company is developing the Tails One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. For more information, visit .

Investor Contact

Media & Investors

Emily Faucette



415-595-9407



EN
28/04/2021

Underlying

TLISTalis Biomedical

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Talis Biomedical

 PRESS RELEASE
Free
TLIS Talis Biomedica...

Talis Biomedical Announces Exploration of Strategic Alternatives and C...

Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that t...

November 14, 2023 1 EN
 PRESS RELEASE
Free
TLIS Talis Biomedica...

Talis Biomedical Announces Second Quarter 2023 Financial Results and B...

Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended June 30, 2023, and provided a business update. Recent Business Highlights Initiated clinical study t...

August 10, 2023 1 EN
 PRESS RELEASE
Free
TLIS Talis Biomedica...

Talis Biomedical to Report Second Quarter 2023 Financial Results and P...

Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023 REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding confe...

August 3, 2023 1 EN
 PRESS RELEASE
Free
TLIS Talis Biomedica...

Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Ch...

Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO) REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023. Dr. Lukowiak has more than 20 years of senior leadership experience in the clinica...

August 2, 2023 1 EN
 PRESS RELEASE
Free
TLIS Talis Biomedica...

New Data Presented at the Infectious Disease Society for Obstetrics an...

New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu Preliminary data suggest a chlamydia, gonorrhea and trichomonas (CT/NG/TV) multiplex test is feasible on a molecular point-of-care (POC) test system with time to result in less than 30 minutes Ability to effectively lyse challenging fungal pathogens, including Candida, in under four minutes on Talis One® system positions Company to develop POC vaginal infection panel REDWOOD CITY, Calif., July 27, 2023 (GLOBE NE...

July 27, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch